Mohammad AskarPublic working copy · medical review pending

Glaucoma · 013

Angle closure: acute care, mechanisms and long-term management

Recognise the emergency first, then distinguish anatomical risk from glaucoma and choose treatment for the actual mechanism.

Working copy published: 2026-11-06T03:47:16+01:00. Source, translation and medical checks remain open. Limitations are stated in the text and references. Editorial text version: 2026-11-04 16:04 CET.

Acute symptomatic angle closure needs immediate ophthalmic treatment. LPI addresses pupillary block; lens-related and secondary mechanisms need their own assessment.

Terminology and draft status

Selected Arabic terms were directly checked in WHO UMD; exact matches and missing compounds are recorded in the terminology ledger. Remaining compounds and full clinical translations remain working copies for further review. Source and medical checks remain pending.

01Recognise and treat the acute emergency

Sudden painful red eye, blurred vision or haloes with headache, nausea or vomiting can indicate acute angle closure. A mid-dilated poorly reactive pupil, corneal oedema and a shallow peripheral anterior chamber support the diagnosis; obtain urgent ophthalmic assessment and begin treatment without delay. 1 2

Measure intraocular pressure (IOP) and confirm the angle mechanism. Pressure is often very high, but no single pressure threshold or fixed interval to irreversible damage defines safety; do not wait for a numerical cutoff or for several hours to pass. 1 2

Take a medication, allergy and systemic history while arranging urgent care. Topical aqueous suppressants, systemic acetazolamide when suitable, anti-inflammatory treatment, analgesia and antiemesis are selected under supervision; beta-blockers and alpha-agonists need their own contraindication checks. 1 2

Severe renal disease, relevant drug allergy and metabolic or electrolyte risks affect systemic treatment; mannitol requires cardiorenal and fluid assessment. 1 2

Pilocarpine is used for a pupillary-block mechanism, but may fail while the iris sphincter is ischaemic at very high IOP. EGS advises deferral at IOP ≥40 mmHg until pressure falls; this is a treatment-context threshold, not an emergency diagnostic rule. 1 2

Avoid intensive repeated dosing and do not use miotics for lens-induced or retrolenticular closure, where cycloplegia is used instead. 1 2

Laser peripheral iridotomy (LPI) relieves pupillary block by connecting the posterior and anterior chambers; it does not create a new trabecular outflow route. Perform it as soon as the cornea and patient permit. If medication does not break the attack or corneal oedema prevents LPI, specialist escalation may include iridoplasty, surgical iridectomy or cyclodiode according to the mechanism and response. 1 2

02Separate anatomical risk, closure and damage

Primary angle-closure suspect (PACS), primary angle closure (PAC) and primary angle-closure glaucoma (PACG) describe different clinical states. Iridotrabecular contact (ITC) means iris contact with the trabecular meshwork; peripheral anterior synechiae (PAS) are fixed adhesions. EGS uses ITC ≥180°, rather than the original strict >180° threshold. 1

Examine the optic disc, retinal nerve fibre layer (RNFL), optical coherence tomography (OCT) and reliable visual fields. PACG is defined by glaucomatous optic neuropathy; do not require every structural and field test to be abnormal simultaneously before recognising damage. Chronic closure can be asymptomatic, while an acute attack can occur before established glaucoma. 1

Separate anatomical risk, closure and damage
StageMeaningDiagnostic findings
PACSAnatomical riskITC ≥180°; normal IOP; no PAS or glaucomatous optic neuropathy.
PACClosure without glaucomaITC ≥180° plus raised IOP and/or PAS; no glaucomatous optic neuropathy.
PACGGlaucomatous diseaseITC ≥180° with glaucomatous optic neuropathy; assess the visual field and stage.

03Identify the mechanism before choosing treatment

In pupillary block, resistance at the pupil creates a pressure difference and bows the peripheral iris forward (iris bombé). The peripheral chamber is shallower than the central chamber. Relieving this component does not reverse established PAS or guarantee normal long-term outflow. 1

Anterior ciliary processes can support a plateau-iris configuration with a relatively deep central chamber and crowded peripheral angle. The double-hump sign during indentation supports this mechanism; ultrasound biomicroscopy (UBM) can show the ciliary anatomy. 1

Plateau-iris syndrome describes persistent appositional closure after a patent iridotomy has removed pupillary block. 1

A thick, anteriorly positioned, intumescent or displaced lens can crowd the angle and shallow the chamber centrally and peripherally. Lens vault measures the anterior lens surface relative to the line joining the scleral spurs. Use the full anatomy and clinical state to decide on lens surgery; a single lens-vault measurement does not prove that LPI will fail. 1

Aqueous misdirection, also called malignant glaucoma, produces forward displacement of the iris–lens diaphragm and uniform chamber shallowing, often after surgery. Exclude pupillary block and choroidal causes. 1

Cycloplegia and aqueous suppression are initial options; miotics are contraindicated. A patent iridotomy must be present, but further treatment may require laser or surgery according to lens status. 1

In selected pseudophakic eyes, zonulo-hyaloido-vitrectomy (ZHV) creates communication through the zonules, anterior hyaloid and vitreous; this explains the teaching expression “unicameral eye”. It is not a universal first operation or a guarantee against recurrence. Phakic eyes may need a posterior approach with or without lens extraction. 1

04Use gonioscopy and imaging together

Static gonioscopy documents the extent of closure; indentation tests whether the angle opens. Apposition can open with indentation, whereas established PAS remain adherent. Interpret mixed areas together rather than assigning an entire eye to a single sign. 1

Anterior-segment OCT (AS-OCT) documents angle width and lens vault without contact, but does not replace dynamic gonioscopy or reliably identify every PAS. UBM is particularly helpful for plateau iris, lens position and posterior pushing mechanisms. Use central and peripheral chamber depth as clues, then verify the cause. 1

The original terms “Volcano Sign” and “So-was-Effekt” are retained in the terminology record, but an authoritative definition and diagnostic performance remain unresolved. Describe the observed iris–lens anatomy directly. A named sign or a lens-vault cutoff should not substitute for mechanism-based assessment. 1

05Discuss prevention in PACS with absolute risk

ZAP randomised one eye of each of 889 community-screened Chinese participants aged 50–70 years with bilateral PACS to LPI; the fellow eye was untreated. 6

At 6 years, composite closure events occurred in 19 treated versus 36 control eyes; rates were 4.19 versus 7.97 per 1000 eye-years, HR 0.53 (95% CI 0.30–0.92). The endpoint combined pressure elevation, PAS or an acute attack, rather than visual loss. 6

The 14-year extension reported 33 versus 105 composite events, HR 0.31 (95% CI 0.21–0.46); acute attacks occurred in 1 versus 5 eyes and PACG in 2 versus 4. 7 8

However, 390 treated and 388 control eyes were lost to follow-up. The published correction changes a baseline depth predictor, without changing the reported overall results and conclusions. Rare sight-threatening outcomes and attrition still limit certainty about long-term visual benefit. 7 8

ANA-LIS enrolled 480 clinic patients over 50 years with bilateral asymptomatic PACS. At 5 years, the composite endpoint occurred in 24 LPI eyes (5.0%) versus 45 control eyes (9.4%); adjusted HR 0.55 (95% CI 0.37–0.83), NNT 22 (95% CI 12.8–57.5). 9

This paired-eye trial supports reduced PAC/PACG endpoints, but its clinic population and endpoint definitions differ from ZAP; do not pool the percentages as an individual prognosis. 9

Observation with regular review is reasonable for many low-risk PACS eyes; prophylactic LPI is considered when additional risk makes the balance more favourable. Examples include necessary repeated dilation, marked hypermetropia, relevant family history, inability to report symptoms or remote access to emergency care. Diabetes matters when it creates a need for retinal examination and dilation, not as an automatic LPI indication by itself. 1 2

06Choose lens treatment for the relevant population

EAGLE randomised 419 participants aged ≥50 years without cataract to clear-lens extraction or standard LPI with medication as needed. Eligibility was newly diagnosed PAC with IOP ≥30 mmHg or PACG; advanced glaucoma and previous acute attacks were excluded. 4 5

At 36 months, extraction improved health-status score by 0.052 (95% CI 0.015–0.088) and lowered IOP by 1.18 mmHg (95% CI 0.38–1.99) relative to standard care. 4 5

This was an unmasked treatment comparison, with complete health-status data for 351 participants and IOP data for 366. The modest mean pressure difference and patient-reported benefit must be weighed against surgery, loss of accommodation and the individual target pressure. The trial does not justify clear-lens extraction for all PACS or claim that lens surgery alone cures every PACG eye. 4 5

Symptomatic cataract and lens crowding favour lens extraction, but timing follows pressure control, corneal clarity, inflammation and surgical risk. RCOphth discusses early surgery approximately 1–4 weeks after presentation in cataract-associated acute closure; EGS stresses operating when the eye is quiet. This is not a mandatory waiting interval or a universal schedule for every mechanism. 1 2

After an acute attack, shallow chamber, endothelial injury, poor dilation and zonular weakness can complicate phacoemulsification. Lens extraction widens the angle but may not restore damaged trabecular function or undo PAS. The original percentage hierarchy for acute closure, chronic PACG, pseudoexfoliation and POAG lacks a verified common comparison; do not use it as a prediction or ranking. 1

07Assess additional surgery without a blanket MIGS rule

Goniosynechialysis (GSL) mechanically separates PAS, but anatomical opening need not add pressure benefit to phaco alone. 10

In a randomised trial of 78 cataract/PAC or PACG eyes with ≥90° PAS, success at 1 year was 52.5% with phaco alone versus 57.9% with phaco-GSL; difference 5.4% (95% CI −18.0 to 28.2), p=0.63. The wide interval and short follow-up do not prove equivalence or rule out benefit in every subgroup. 10

Gonioscopy-assisted transluminal trabeculotomy (GATT), Kahook Dual Blade (KDB) and OMNI act on different parts of the conventional outflow pathway and require suitable angle access. Mean deviation (MD) alone is not an indication. In advanced or progressing disease with a low target pressure, consider whether a trabecular procedure can realistically achieve it; filtering surgery or another approach may be needed. 1 12

The original “Bank-Technik” remains an unresolved source term for manual goniotomy; it is not silently renamed BANG. A separate 2026 BANG–GATT trial studied mild/moderate pseudophakic POAG, explicitly excluding angle closure, and used a 23G bent needle for a 90° BANG procedure. 12

It does not verify the original 25–30G/90–120° recipe, KDB/OMNI equivalence or a cost advantage in PACG. 12

08Review secondary causes and prevent recurrence

Topiramate can cause supraciliary effusion with forward movement of the iris–lens diaphragm, often bilateral closure and an acute myopic shift. Seek urgent specialist care and coordinate rapid withdrawal with the prescriber, particularly in epilepsy. Use mechanism-directed pressure control, cycloplegia and anti-inflammatory treatment; miotics can worsen this non-pupillary mechanism, and LPI does not correct the effusion itself. 1 2 11

Uveitis, posterior synechiae with iris bombé, neovascular membranes, lens displacement and other posterior pushing causes need cause-specific care. A treatment that helps pupillary block may worsen another mechanism. Do not apply a single acute-primary algorithm to all secondary angle closure. 1 2

After the attack, reassess gonioscopy, iridotomy patency, IOP, PAS, optic nerve and visual field, then set follow-up and target pressure. The phakic fellow eye with the same anatomical risk generally needs prompt prophylactic LPI, ideally during the acute-care episode or before discharge. 1 2

Existing lens extraction, a patent iridotomy and a secondary mechanism change that decision; unilateral drug-related closure does not prove identical pupillary-block risk in the fellow eye. 1 2

Use the angle-closure guideline that actually addresses the mechanism and setting. The official DOG/BVA list labels 15a as POAG/NTG/OHT and 15b as childhood glaucoma; 15a excludes angle closure. It therefore cannot support the original attribution of a complete German acute-angle-closure algorithm or a medicolegal verdict about a missed test. 1 2 3

Review secondary causes and prevent recurrence
TopicFinding / mechanismEvidence / next stepImaging / examinationCaution
PACSITC ≥180°, normal IOPObserve or select LPI by added risk; ZAP/ANA-LISGonioscopy; AS-OCT supplementaryDiabetes/travel alone is not a universal indication.
PAC/PACGRaised IOP/PAS; glaucoma distinguishes PACGEAGLE supports selected lens extractionGonioscopy, RNFL/OCT and fieldConsider age, accommodation and target pressure.
Acute attackPain, oedema, closed angle, often high IOPImmediate pressure control; LPI for pupillary blockSlit lamp, tonometry, gonioscopyAssess the fellow eye; no safe waiting period.
Plateau irisAnterior ciliary processes; peripheral crowdingRelieve coexisting pupillary block; reassess after LPIDouble-hump sign; UBM anatomyPatent LPI does not exclude persistent closure.
Lens-relatedLens crowding; central and peripheral shallowingConsider lens surgery by clinical stateAS-OCT lens vault; UBM if neededNo verified universal vault cutoff for LPI failure.
Malignant glaucomaAqueous misdirection; uniform shallowingCycloplegia; selected laser or ZHV / vitrectomyExclude pupillary block and choroidal causesNo miotics; treatment depends on lens status.
Secondary closureUveitis, membranes, topiramate effusionTreat cause and mechanismUBM for effusion / posterior pushingTopiramate: coordinate withdrawal; avoid miotics.
How quickly must an acute attack be treated?

Immediately. Do not wait for a fixed pressure or time threshold; lower pressure and relieve the responsible mechanism under urgent specialist care.

What should be done for the fellow eye?

Assess its anatomy, lens status and iridotomy. Prompt prophylactic LPI is generally indicated in the phakic anatomically at-risk fellow eye after primary acute closure; secondary mechanisms and existing treatment alter the decision.

References and access status

  1. 1
    EGS 6th edition, 2025 — angle closure / aqueous misdirection

    Selected text read: mechanisms, classification, diagnosis, PACS/PAC/PACG, acute care, post-acute surgery and aqueous misdirection, printed pp138–149/153. Not the complete guideline or every source trial.

  2. 2
    RCOphth — Management of Angle-Closure Glaucoma, June 2022

    Official PDF retrieved; cover and selected acute-care text/pathway, printed pp20–24, read as extraction. Evidence search December2020; review due June2025. The2026 hosting path is not a new edition; no full-guideline or pixel inspection claimed.

  3. 3
    DOG/BVA — official guideline list and scope of15a

    Official list and15a first-page scope inspected.15a concerns POAG/NTG/OHT (2006) and excludes angle closure;15b concerns childhood glaucoma (1998). No applicable current German acute algorithm verified.

  4. 4
    Azuara-Blanco et al. — EAGLE, Lancet2016; PMID27707497

    Complete primary abstract read; main report, protocol and supplements not read. Abstract subgroup counts do not sum to the stated total; no silent reconciliation.

  5. 5
    Mitchell et al. — EAGLE secondary analysis, BJO2023

    Selected primary methods and eligibility text read, including advanced-glaucoma and prior-acute-attack exclusions. Not the full analysis or supplements.

  6. 6
    He et al. — ZAP6-year RCT, Lancet2019; PMID30878226

    Complete primary abstract and indexed selected design/results passages read; main tables, protocol and supplements not fully read.

  7. 7
    Yuan et al. — ZAP14-year extension, Ophthalmology2023; PMID37030454

    Complete indexed primary abstract and selected primary results/table extractions inspected; linked indexed correction now read. Not complete report, figures or supplements.

  8. 8
    ZAP14-year corrigendum, Ophthalmology2024; PMID38128972

    Complete indexed correction notice inspected: the abstract predictor is shallower, not greater, central anterior chamber depth. The notice states that overall results and conclusions are unchanged. Direct page retrieval returned403; no PDF/pixel inspection claimed.

  9. 9
    Baskaran et al. — ANA-LIS5-year RCT; PMID34453952

    Complete indexed primary abstract read. Full report, tables, protocol and supplements not read.

  10. 10
    Husain et al. — phaco ± GSL RCT, JAMA Ophthalmology2019; PMID31294768

    Complete primary abstract read. Full report, protocol and supplements not read; absence of significant difference is not equivalence.

  11. 11
    DailyMed — topiramate label, section5.1

    Current hosted US label section5.1 (version20260128) read. Not a German product label or the full prescribing information; withdrawal requires treating-team judgement.

  12. 12
    Ayub/Costa — BANG vs GATT24-month RCT, Eye2026

    Primary abstract and selected methods/eligibility/procedure/results passages read. Small POAG study excludes angle closure. Original Bank identity remains unresolved; full supplements not read. Earlier review004 records an abstract/body success-rate discrepancy.

Original lecture links